Ad
related to: maintenance rituximab mantle cell lymphoma life expectancy
Search results
Results from the WOW.Com Content Network
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. [ 1 ] [ 2 ] It is named for the mantle zone of the lymph nodes where it develops. [ 3 ] [ 4 ] The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.
R-HDAC, or R-HD-AraC (ituximab plus (H)igh (D)ose ra-) is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine. [1]
The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab. [ 33 ] R-CHP with polatuzumab vedotin , an antibody-drug conjugate, was included as a category 1 preferred regimen for first-line DLBCL by the National ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
R-miniCHOP is indicated in elderly patients (>80 years) with diffuse large B-cell lymphoma due to less toxicity from the reduced dose in comparison to R-CHOP. R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine). [3]
Aggressive lymphoma, also known as high-grade lymphoma, is a group of fast growing non-Hodgkin lymphoma. [1]There are several subtypes of aggressive lymphoma. These include AIDS-associated lymphoma, angioimmunoblastic lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and peripheral T-cell lymphoma. [1]
Mantle cell lymphoma: The monoclonal B-cells in this aggressive lymphoma are CD5+ in most cases, CD10−, CD23−, CD43+, CD103−, complete Ig+, and express cyclin D1; these cells have translocations between chromosomes 11 and 14 in >95% of cases and in many cases overexpress the SOX11 transcription factor gene. [2]
In situ lymphoid neoplasia (ISLN, also termed in situ lymphoma) is a precancerous condition newly classified by the World Health Organization in 2016. The Organization recognized two subtypes of ISLN: in situ follicular neoplasia (ISFN) and in situ mantle cell neoplasia (ISMCL). [1]
Ad
related to: maintenance rituximab mantle cell lymphoma life expectancy